Novavax, Inc. (NASDAQ:NVAX) Holdings Lowered by BNP Paribas Financial Markets

BNP Paribas Financial Markets reduced its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 59.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,156 shares of the biopharmaceutical company's stock after selling 208,295 shares during the period. BNP Paribas Financial Markets owned about 0.09% of Novavax worth $1,808,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of Montreal Can boosted its holdings in Novavax by 26.7% in the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company's stock valued at $32,643,000 after purchasing an additional 517,727 shares during the last quarter. Shah Capital Management raised its position in shares of Novavax by 19.0% in the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company's stock valued at $122,322,000 after purchasing an additional 1,544,263 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Novavax by 110.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company's stock valued at $6,296,000 after buying an additional 261,464 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Novavax by 16.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company's stock worth $16,741,000 after buying an additional 187,548 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Novavax in the second quarter worth $1,251,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Stock Up 7.7 %

NVAX stock traded up $0.64 during mid-day trading on Friday, reaching $8.94. The company had a trading volume of 7,104,654 shares, compared to its average volume of 5,298,804. Novavax, Inc. has a one year low of $3.53 and a one year high of $23.86. The stock has a market capitalization of $1.43 billion, a P/E ratio of -3.96 and a beta of 2.02. The stock's 50-day simple moving average is $9.99 and its two-hundred day simple moving average is $12.38.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same quarter in the prior year, the business earned ($1.26) earnings per share. The company's revenue for the quarter was down 54.8% compared to the same quarter last year. On average, research analysts forecast that Novavax, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group dropped their target price on shares of Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, October 16th. HC Wainwright reaffirmed a "buy" rating and set a $19.00 target price on shares of Novavax in a report on Tuesday, November 12th. B. Riley reiterated a "buy" rating and issued a $26.00 price target (up from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. raised their price objective on Novavax from $8.00 to $9.00 and gave the stock an "underweight" rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $17.83.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.